Meeting NewsVideo

VIDEO: Alimera highlights Iluvien research at ARVO

VANCOUVER, British Columbia — Samer Kaba, MD, the new chief medical officer at Alimera Sciences, discusses research regarding Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), the company’s diabetic macular edema treatment, at the Association for Research in Vision and Ophthalmology meeting.

VANCOUVER, British Columbia — Samer Kaba, MD, the new chief medical officer at Alimera Sciences, discusses research regarding Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), the company’s diabetic macular edema treatment, at the Association for Research in Vision and Ophthalmology meeting.

    See more from Association for Research in Vision and Ophthalmology